PMID- 24127999
OWN - NLM
STAT- MEDLINE
DCOM- 20140929
LR  - 20221207
IS  - 1753-0407 (Electronic)
IS  - 1753-0393 (Print)
IS  - 1753-0407 (Linking)
VI  - 6
IP  - 2
DP  - 2014 Mar
TI  - Role of premixed insulin analogues in the treatment of patients with type 2 
      diabetes mellitus: a narrative review.
PG  - 100-10
LID - 10.1111/1753-0407.12096 [doi]
AB  - Because of the progressive nature of type 2 diabetes mellitus (T2DM), insulin 
      therapy will eventually become necessary in most patients. Recent evidence 
      suggests that maintaining optimal glycemic control by early insulin therapy can 
      reduce the risk of microvascular and macrovascular complications in patients with 
      T2DM. The present review focuses on relevant clinical evidence supporting the use 
      of premixed insulin analogues in T2DM when intensifying therapy, and as starter 
      insulins in insulin-naive patients. Our aim is to provide relevant facts and 
      clinical evidence useful in the decision-making process of treatment selection 
      and individualized treatment goal setting to obtain sustained blood glucose 
      control.
CI  - (c) 2013 The Authors. Journal of Diabetes published by Ruijin Hospital, Shanghai 
      Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.
FAU - Elizarova, Svetlana
AU  - Elizarova S
AD  - Department of Endocrinology, Eli Lilly Vostok S.A., Moscow, Russian Federation.
FAU - Galstyan, Gagik R
AU  - Galstyan GR
FAU - Wolffenbuttel, Bruce H R
AU  - Wolffenbuttel BH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140121
PL  - Australia
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
RN  - 0 (Biphasic Insulins)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Insulin, Long-Acting)
RN  - 0 (Insulin, Short-Acting)
RN  - 0 (insulin aspart, insulin aspart protamine drug combination 30:70)
RN  - 2ZM8CX04RZ (Insulin Glargine)
RN  - 53027-39-7 (Insulin, Isophane)
RN  - D933668QVX (Insulin Aspart)
SB  - IM
MH  - Biphasic Insulins/therapeutic use
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/*therapeutic use
MH  - Insulin Aspart/therapeutic use
MH  - Insulin Glargine
MH  - Insulin, Isophane/therapeutic use
MH  - Insulin, Long-Acting/therapeutic use
MH  - Insulin, Short-Acting
MH  - Treatment Outcome
PMC - PMC4285786
OTO - NOTNLM
OT  - HbA1c
OT  - glycated hemoglobin
OT  - premixed insulin analogue
OT  - type 2 diabetes mellitus
OT  - 糖化血红蛋白，HbA1c，预混胰岛素类似物，2型糖尿病
EDAT- 2013/10/17 06:00
MHDA- 2014/09/30 06:00
PMCR- 2015/01/07
CRDT- 2013/10/17 06:00
PHST- 2012/12/13 00:00 [received]
PHST- 2013/09/30 00:00 [revised]
PHST- 2013/10/09 00:00 [accepted]
PHST- 2013/10/17 06:00 [entrez]
PHST- 2013/10/17 06:00 [pubmed]
PHST- 2014/09/30 06:00 [medline]
PHST- 2015/01/07 00:00 [pmc-release]
AID - 10.1111/1753-0407.12096 [doi]
PST - ppublish
SO  - J Diabetes. 2014 Mar;6(2):100-10. doi: 10.1111/1753-0407.12096. Epub 2014 Jan 21.